Porifera, commonly referred to as marine sponges, are acknowledged as major producers of marine natural products (MNPs). Sponges of the genus Phorbas have attracted much attention over the years. They are widespread in all continents, and several structurally unique bioactive compounds have been identified from this species.
Name | Class | Species | Cell Lines | Dose/Concentration | Reference | |
---|---|---|---|---|---|---|
13 | Zarzissine | Alkaloid | Phorbas | tenacior | P-388 |
Compound | Class | Species | Biological Activity | Dose/Concentration | Reference | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | a | IC | 50 | 12 µg/mL | [ | 37] | [22] | |||||||||||||||
Anchinopeptolide A | Alkaloid | P. tenacior | Displacement of specific ligands from their biochemical receptors | 5 µg/mL-average inhibition values roughly 35–40% in all receptor binding | [ | 21,22] | [37][38] | KB | b | IC | 50 | 5 µg/mL | ||||||||||
2 | Anchinopeptolide B | Alkaloid | P. tenacior | Displacement of specific ligands from their biochemical receptors | 5 µg/mL-71% human B2 bradykinin receptor; 80% neuropeptide Y receptor | [21, | [37 | 22] | ][38] | |||||||||||||
3 | Anchinopeptolide C | Alkaloid | P. tenacior | NSCLC-N6 | c | IC | 50 | 10 µg/mL | ||||||||||||||
Displacement of specific ligands from their biochemical receptors | 5 µg/mL-62% somatostatin receptor; 52% human B2 bradykinin receptor; 57% neuropeptide Y receptor | [ | 21 | , | 22 | ] | [37][38] | 17 | Phorboxazole A | |||||||||||||
4 | Macrolide | Anchinopeptolide D | Phorbas | sp. | AlkaloidHCT-116 | d | P. tenacior | GI | 50 | 4.36 × 10 | Displacement of specific ligands from their biochemical receptors | −10 | M | 5 µg/mL-77% somatostatin receptor | [24] | [23] | ||||||
[ | 21 | , | 22 | ] | [ | 37][38] | HT29 | d | GI | 50 | 3.31 × 10 | −10 | M | |||||||||
19 | Muironolide A | Macrolide | Phorbas | sp. | HCT-116 | d | IC | 50 | 96.5 μg/mL | [40] | [24] | |||||||||||
20 | Phorbaside A | Macrolide | Phorbas | sp. | HCT-116 | d | IC | 50 | 30.0 μM | [44] | [25] | |||||||||||
22 | Phorbaside C | Macrolide | Phorbas | sp. | HCT-116 | d | IC | 50 | 2 μM | [44] | [25] | |||||||||||
23 | Phorbaside D | Macrolide | Phorbas | sp. | HCT-116 | d | IC | 50 | 61.9 μM | [44] | [25] | |||||||||||
24 | Phorbaside E | Macrolide | Phorbas | sp. | HCT-116 | d | IC | 50 | 10.2 μM | [44] | [25] | |||||||||||
29 | Phorbasterone A | Steroid | Phorbas | amaranthus | HCT-116 | d | IC | 50 | 1–3 µg/mL | [48,73] | [26][27] | |||||||||||
30 | Phorbasterone B | Steroid | Phorbas | amaranthus | HCT-116 | d | IC | 50 | 1–3 µg/mL | [48,73] | [26][27] | |||||||||||
31–32 | Phorbasterone C | Steroid | Phorbas | amaranthus | HCT-116 | |||||||||||||||||
13 | Zarzissine | Alkaloid | P. topsenti | Antimicrobial | Paper disk agar-(100 µg, purified product) 12,10, and 11 mm | [37] | [22] | |||||||||||||||
14 | p | -Hydroxybenzaldehyde | Alkaloid | P. topsenti | Antimicrobial | Paper disk agar-(100 µg, purified product) 8,7, and 7 mm | [37] | [22] | ||||||||||||||
14 | Phorbatopsin A | Alkaloid | P. topsenti | Antioxidant | ORAC | FL | 0.88 ± 0.28 | [26] | [39] | |||||||||||||
15 | Phorbatopsin B | Alkaloid | P. topsenti | Antioxidant | ORAC | FL | 0.50 ± 0.08 | [26] | [39] | |||||||||||||
16 | Phorbatopsin C | Alkaloid | P. topsenti | Antioxidant | ORAC | FL | 0.21 ± 0.02 | [26] | [39] | |||||||||||||
17 | Phorboxazole A | Macrolide | Phorbas | sp. | Antifungal | Agar disk diffusion assay- | C. albicans | : 12 mm (1 µg) and 9 mm (0.1 µg); | Saccharomyces carlsbergensis | : 1, 20 mm (1 µg), and 13 mm (0.1 µg) | [24] | [23] | ||||||||||
18 | Phorboxazole B | Macrolide | Phorbas | sp. | Antifungal | Agar disk diffusion assay-C. albicans: 11 mm (1 µg) and 8 mm (0.1 µ g); | Saccharomyces carlsbergensis | : 1, 16 mm (1 µg), and 10 mm (0.1 µg) | [24] | [23] | ||||||||||||
19 | Muironolide A | Macrolide | Phorbas | sp. | Antifungal | MIC 16 μg/mL | [40] | [24] | d | IC | 50 | 1–3 µg/mL | [48 | |||||||||
22 | , | 73 | Phorbaside C | ] | [ | 26][27] | ||||||||||||||||
Macrolide | Phorbas | sp. | Macrophage infectivity potentiator (Mip) | Binding affinity of 75 with Chlamydia pneumoniae | [ | 88] | [40] | 33–34 | Phorbasterone D | Steroid | Phorbas | amaranthus | HCT-116 | d | IC | |||||||
37 | Amaroxocane A | Steroid | 50 | P.amaranthus | 1–3 µg/mL | Anti-predatory activity | [48, | Little feeding deterrence (8/10 pellets eaten) | 73] | [26][27] | ||||||||||||
[ | 50 | ] | [ | 41 | ] | 45 | Phorbaketal A | Sesterterpenoid | Phorbas | sp. | A549 | c | IC | 50 | 11–12 µg mL | −1 | [52 | |||||
38 | , | 54 | ] | [ | 28 | ][ | Amaroxocane B29] | |||||||||||||||
Steroid | P. amaranthus. | Anti-predatory activity | Significant deterrent activity (3/10 pellets eaten) | [ | 50 | ] | [41] | HT-29 | d | IC | 50 | 11–12 µg mL | −1 | |||||||||
45 | Phorbaketal A | Sesterterpenoid | Phorbas | sp. | Osteogenic differentiation Anti-inflammatory |
Phorbaketal A stimulates TAZ-mediated osteoblast differentiation through the activation of extracellular signal-regulated kinase (1–10 µg/mL) Dose dependent inhibition of LPS-induced production of inflammatory cytokines and the transcriptional activity NF-κB (2.5, 5, and 10 μM) and adipocyte differentiation through transcriptional coactivator with PDZ-binding motif (1–10 µg/mL) |
[84] [82,83] | [42] [43][44] |
HepG2 | e | IC | 50 | 11–12 µg mL | −1 | ||||||||
60 | Alotaketal A | Sesterterpenoid | Phorbas | sp. | cAMP signaling activation | cAMP cell signaling pathway-EC | 50 | of 18 nM | [55] | [45] | 46 | Phorbaketal B | Sesterterpenoid | Phorbas | sp. | A549 | c | IC | 50 | 12–460 µg/mL | [52,54] | [28][29] |
61 | Alotaketal B | Sesterterpenoid | Phorbas | sp. | cAMP signaling activation | cAMP cell signaling pathway-EC | 50 | of 240 nM | [55] | [45] | HT-29 | d | IC | 50 | 12–460 µg/mL | |||||||
62 | Alotaketal C | Sesterterpenoid | Phorbas | sp. | Latency-reversing agent (LRA) | HIV-1 provirus/GFP expression of J-Lat 9.2 cells-1 μM | [56, | [ | 57, | 46 | 78] | ][47][48] | HepG2 | e | IC | 50 | 12–460 µg/mL | |||||
63 | Alotaketal D | Sesterterpenoid | Phorbas | sp. | Latency-reversing agent (LRA) | HIV-1 provirus/GFP expression of J-Lat 9.2 cells-30 μM | [56,57,78] | [46][47][48] | 47 | Phorbaketal C | Sesterterpenoid | Phorbas | sp. | |||||||||
65 | Ansellone A | A549 | Sesterterpenoid | c | Phorbas | sp. | cAMP signaling activation Latency-reversing agent (LRA)cAMP activatorIC | 50 | 12–460 µg/mL | cAMP cell signaling pathway-EC | [52,54] | [28][29] | ||||||||||
50 | of 14 µM | HIV-1 provirus/GFP expression of J-Lat 9.2 cells-30 μM | [ | 57 | ,62] | [47][49] | HT-29 | d | IC | |||||||||||||
66 | Ansellone B | Sesterterpenoid | Phorbas | sp. | 50 | 12–460 µg/mL | Inhibition of inducible NOS (iNOS) | |||||||||||||||
RAW 264.7 LPS-activated mouse macrophage cells-IC | 50 | = f 4.5 μM, | [ | 66 | ] | [50] | HepG2 | e | IC | 50 | 12–460 µg/mL | |||||||||||
73 | Anvilone A | Sesterterpenoid | Phorbas | sp. | Latency-reversing agent (LRAs) | HIV-1 provirus/GFP expression of J-Lat 9.2 cells-30 μM | [57] | HT-29 | d | LG | 50 | 5–15 μM | ||||||||||
] | [ | 51 | ] | 50 | Phorbaketal N | Sesterterpenoid | Phorbas | sp. | PANC-1 | f | IC | 50 | 11.4 µM | [53] | [30] | |||||||
A498 | g | IC | 50 | 18.7 µM | ||||||||||||||||||
[ | 47 | ] | ||||||||||||||||||||
76 | Phorbasone A | Sesterterpenoid | Phorbas | sp. | Osteogenic properties | Calcium deposition effect at a concentration of 0.5 μg/mL | [65 | |||||||||||||||
79 | Phorbasone A acetate | Sesterterpenoid | Phorbas | sp. | Inhibition of inducible NOS (iNOS) | Inhibitory activity on NOS in RAW 264.7 LPS-activated mouse macrophage cells-IC | 50 | = 2.8 μM | [66] | [50] | ||||||||||||
83 | Oxaspirosuberitenone | Sesterterpenoids | P. areolatus | Antimicrobial | Activity against MRSA at the highest concentration tested (160 µM) | [67] | [31] | |||||||||||||||
94 | Phorbasin H | Diterpenoid | ACHN | g | LC | 50 | 24.4 µM | |||||||||||||||
Phorbas | sp. | Antifungal | Suppression of the hyphal development of | C. albicans | (250 μg/mL) | [86] | [52] | 84 | Isosuberitenone B | Sesterterpenoid | Phorbas | areolatus | ||||||||||
93–95 | Phorbasins | A549 | c | Diterpenoid | Phorbas | sp.IC | 50 | 8.8 μM | [ | Antifungal | EtOH extract-growth inhibitory activity against the gram-positive bacteria | Staphylococcus aureus | and | Micrococcus luteus | –Concentration: N/A | 67] | [31] | |||||
[ | 68 | , | 69 | ] | [ | 53][54] | HT-29 | |||||||||||||||
104 | Gagunin D | Diterpenoid | Phorbas | sp. | d | IC | 50 | 9.0 μM | ||||||||||||||
Anti-melanogenic | IC | 50 | = 5.7 µg/mL; 10 µM on UVB irradiated human skin models demonstrated a considerable reduction melanin biosynthesis | [ | 87 | ] | [55] | HepG2 | e | IC | 50 | 7.4 μM | ||||||||||
MCF-7 | h | IC | 50 | 8.8 μM | ||||||||||||||||||
85 | 19-episuberitenone B | Sesterterpenoid | ||||||||||||||||||||
101–117 | Gagunins | Diterpenoid | Phorbas | sp. | Isocitrate lyase (ICL) inhibition | LC | 50 | of 55–140 µg/mL | [76] | [34] | Phorbas | |||||||||||
125 | Astaxanthin | Carotenoid | P. topsenti | Antioxidant | ORAC | FL | 0.22 ± 0.02 | [26] | [39] | areolatus | A549 | c | ||||||||||
126 | Adonirubin | IC | 50 | 5.1 μM | [ | Carotenoid | 67] | [31] | ||||||||||||||
P. topsenti | Antioxidant | ORAC | FL | 0.024 ± 0.001 | [ | 26] | [39 | HT-29 | d | IC | 50 | 6.4 μM | ||||||||||
] | ||||||||||||||||||||||
127 | Taurine | Sulfonic acid | P. topsenti | Antioxidant | ORAC | FL | 0.083 ± 0.013 | [26] | [39] | |||||||||||||
128 | Taurobetaine | Sulfonic acid | HepG2 | e | IC | 50 | 5.0 μM | |||||||||||||||
P. topsenti | Antioxidant | ORAC | FL | 00.019 ± 0.002 | MCF-7 | h | IC | 50 | 5.1 μM | |||||||||||||
88 | Phorbasin B | Diterpene | Phorbas | sp. | A549 | c | LG | 50 | 5–15 μM | [70] | [32] | |||||||||||
HT-29 | d | LG | 50 | 5–15 μM | ||||||||||||||||||
89 | Phorbasin C | Diterpene | Phorbas | sp. | A549 | c | LG | 50 | 5–15 μM | [70] | [32] | |||||||||||
HT-29 | d | LG | 50 | 5–15 μM | ||||||||||||||||||
91 | Phorbasin E | Terpenyl-taurine | Phorbas | sp. | A549 | c | LG | 50 | 5–15 μM | [70] | [32] | |||||||||||
HT-29 | d | LG | 50 | 5–15 μM | ||||||||||||||||||
101 | Gagunin A | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 50.1 µg/mL | [75] | [33] | |||||||||||
102 | Gagunin B | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 10.4 µg/mL | [75] | [33] | |||||||||||
103 | Gagunin C | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 0.71 µg/mL | [75] | [33] | |||||||||||
104 | Gagunin D | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 0.13 µg/mL | [75] | [33] | |||||||||||
105 | Gagunin E | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 0.03 µg/mL | [75] | [33] | |||||||||||
106 | Gagunin F | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 0.11 µg/mL | [75] | [33] | |||||||||||
107 | Gagunin G | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 2.0 µg/mL | [75] | [33] | |||||||||||
108 | Gagunin H | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 10.0 µg/mL | [76] | [34] | |||||||||||
109 | Gagunin I | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 11.5 µg/mL | [76] | [34] | |||||||||||
110 | Gagunin J | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 9.1 µg/mL | [76] | [34] | |||||||||||
111 | Gagunin K | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 17.5 µg/mL | [76] | [34] | |||||||||||
112 | Gagunin L | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 12.5 µg/mL | [76] | [34] | |||||||||||
113 | Gagunin M | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 0.71 µg/mL | [76] | [34] | |||||||||||
114 | Gagunin N | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | > 50 µg/mL | [76] | [34] | |||||||||||
115 | Gagunin O | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 11.1 µg/mL | [76] | [34] | |||||||||||
116 | Gagunin P | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | 8.5 µg/mL | [76] | [34] | |||||||||||
117 | Gagunin Q | Diterpenoid | Phorbas | sp. | K-562 | a | LC | 50 | > 50 µg/mL | [76] | [34] | |||||||||||
118 | Gukulenin A | tetraterpenoid | Phorbas | gukulensis | HCT-116 | d | IC | 50 | 62 nM | [30] | [35] | |||||||||||
FaDu | b | IC | 50 | 57 nM | ||||||||||||||||||
SN12C | g | IC | 50 | 92 nM | ||||||||||||||||||
MKN45 | j | IC | 50 | 0.13 nM | ||||||||||||||||||
TOVG-21G | i | IC | 50 | 0.04 μM | [80] | [36] | ||||||||||||||||
[ | 26 | ] | [ | 39 | ] | OVCAR-3 | i | IC | 50 | 0.13 μM | ||||||||||||
A2780 | i | IC | 50 | 0.03 μM | ||||||||||||||||||
SKOV3 | i | IC | 50 | 0.36 μM | ||||||||||||||||||
119 | Gukulenin B | tetraterpenoid | Phorbas | gukulensis | HCT-116 | d | IC | 50 | 0.55 μM | [30] | [35] | |||||||||||
A2780 | i | |||||||||||||||||||||
FaDu | b | IC | 50 | 0.63 μM | ||||||||||||||||||
SN12C | g | IC | 50 | 0.61 μM | ||||||||||||||||||
MKN45 | j | IC | 50 | 0.72 μM | ||||||||||||||||||
123 | Gukulenin F | Tetraterpenoid | Phorbas | gukulensis | K-562 | a | LC | 50 | 0.4 µM | [30] | [35] | |||||||||||
FaDu | b | IC | 50 | 0.63 μM | ||||||||||||||||||
SN12C | g | IC | 50 | 0.61 μM | ||||||||||||||||||
MKN45 | j | IC | 50 | 0.72 μM |